References in periodicals archive ?
GreenLeaf Genetics LLC is the industry's first joint venture to outlicense corn and soybean genetics to United States and Canadian seed companies, with potential to expand worldwide.
Issues regarding the appropriate scope of protection for intellectual property rights in genetics and genomics research and development will only increase in complexity as progress in these fields continues.
Wallace "mtDNA haplogroups in Native Americans," American Journal of Human Genetics 56 (1995):1234-1236.
Seattle Genetics discovers and develops monoclonal antibody, or mAb-based therapeutics to treat cancer and related diseases.
The CAFC held that there was a single defect in our '195 patent," explained Tom DesRosier, Vice President and Chief Patent Counsel of Genetics Institute.
Yet behavioral genetic data provide a compelling antidote to the increasingly influential notion among psychiatrists that defective genes and broken brains primarily cause mental disorders, asserts psychologist Robert Plomin of Pennsylvania State University in University Park, a leading researcher in human behavioral genetics.
Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including lymphoma, multiple myeloma, leukemia and solid tumors.
Seattle Genetics is developing its own ADC product candidates, including SGN-35, which entered clinical trials in 2006 for patients with Hodgkin's disease and other CD30-positive malignancies, and SGN-75, which is in preclinical development for renal cell cancer and CD70-positive hematologic malignancies.
Genetics Institute, through its newly established Paris office, will have primary responsibility for the GI-Yamanouchi European Partnership in the areas of clinical trials and pan-European market development of the first BMP products for localized bone repair.
We are very interested in the encouraging activity of SGN-40 observed in early clinical trials and we look forward to developing this antibody with Seattle Genetics, in addition to continuing our ongoing collaboration on antibody-drug conjugates," said Hal Barron, M.
In a separate announcement, Crop Genetics reported a collaboration with Imperial Chemical Industries (NYSE: ICI) to assess the commercial feasibility of the InCide bioinsecticide for control of a major corn insect pest.
In the drive to streamline the drug discovery process, biotechnology and pharmaceutical companies are harnessing chemical genetics as a tool to overcome the limitations of traditional target-based drug discovery.
CROP GENETICS REPORTS IMPROVED CONTROL WITH CORN BIOINSECTICIDE
Seattle Genetics presented data from two phase II clinical studies of SGN-30, a monoclonal antibody directed against the CD30 antigen, which is highly expressed on a variety of hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas.
Full browser ?